Prot #CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatm

Project: Research project

Project Details

StatusActive
Effective start/end date6/21/166/21/22

Funding

  • Parexel (Prot #CP-MGAH22-04)
  • Macrogenics, Inc. (Prot #CP-MGAH22-04)